A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors
Phase of Trial: Phase IV
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 15 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.
- 18 Nov 2009 Additional trial location identified as reported by Roche.
- 19 Sep 2009 Status changed from active, no longer recruiting to recruiting as reported by Roche.